Skip to main content
. 2021 Apr 9;9(9):969–976. doi: 10.1016/S2213-2600(21)00043-6

Figure 3.

Figure 3

Kaplan–Meier curve of overall survival of patients retreated with tremelimumab and durvalumab (ICI retreated) versus non-ICI retreated patients who received additional chemotherapy (post-hoc analysis)

Vertical lines indicate censored observations. ICI=immune checkpoint inhibitor.